Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Huntingtin homolog | 0.0127 | 0.1349 | 0.3896 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.1349 | 0.1349 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0031 | 0 | 0.5 |
Echinococcus multilocularis | histone lysine methyltransferase setb histone lysine methyltransferase eggless | 0.0031 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0381 | 0.4899 | 0.4899 |
Plasmodium vivax | SET domain protein, putative | 0.0031 | 0 | 0.5 |
Onchocerca volvulus | 0.0246 | 0.3015 | 0.8705 | |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0031 | 0 | 0.5 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0745 | 1 | 1 |
Echinococcus granulosus | histone lysine methyltransferase setb | 0.0031 | 0 | 0.5 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0031 | 0 | 0.5 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0745 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0127 | 0.1349 | 0.1349 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0745 | 1 | 1 |
Echinococcus multilocularis | histone lysine N methyltransferase SETMAR | 0.0031 | 0 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.0246 | 0.3015 | 0.5 |
Onchocerca volvulus | 0.0278 | 0.3463 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0745 | 1 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0031 | 0 | 0.5 |
Schistosoma mansoni | histone-lysine n-methyltransferase suv9 | 0.0031 | 0 | 0.5 |
Brugia malayi | Pre-SET motif family protein | 0.0216 | 0.2596 | 0.2596 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.1349 | 0.1349 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0216 | 0.2596 | 0.2596 |
Onchocerca volvulus | Huntingtin homolog | 0.0127 | 0.1349 | 0.3896 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Saccharomyces cerevisiae | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.